Irwin Mitchell’s Corporate Team Advises On Deal

A Liverpool-based chemical technology company which is at the forefront of supporting modern-day drug discovery and development has secured £2.25m to help it grow the business further.

Founded in 2014, Liverpool ChiroChem (LCC) is a specialist business which develops the chemical building blocks for use in biopharmaceutical drug design and development. 

LCC has an international portfolio of pharma, biotech and agrochemicals customers which includes Merck, Novartis, Domainex, Syngenta and Bayer.

The additional £2.25m is from its current investors, Praetura Capital, Deepbridge Capital, and Maven, and will be used to fund recruitment, new equipment and the development of new chemical compounds.

Victoria Zivkovic, a Corporate partner at the Manchester office of law firm Irwin Mitchell together with solicitor Greg Mazgajczyk, advised ChiroChem on the deal.

Paul Colbon, CEO at LCC said: “2019 saw a record number of newly approved drugs hit the market. I’m delighted that LCC’s long-term strategic investors are allowing us to ramp up the production and distribution of our novel chemical components that will enable our clients to unlock new chemical space for further discovery of novel drugs and development of treatments in multiple therapeutic indications, particularly oncology and the central nervous system. We have a world-class team in the UK, France and China that are working extremely well together, it’s a joy to witness.”

Expert Opinion

“LCC is an extremely innovative company and it is at the forefront of drug development not just here in the UK, but globally. We are delighted to have worked with them on their latest investment and look forward to seeing the business continue to move forward.” Victoria Zivkovic - Partner